Knockdown of UBE2T inhibits osteosarcoma cell proliferation, migration, and invasion by suppressing the PI3K/Akt signaling pathway

Oncology Research

Volumn 24, Issue 5, 2016, Pages 361-369

  Wang, Yu ^a,b   Leng, Hui ^b   Chen, Hui ^a,c   Wang, Lei ^a   Jiang, Nan ^a   Huo, Xin ^b   Yu, Bin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Chifeng Municipal Hospital   (China)

^c FUZHOU SECOND HOSPITAL AFFILIATED TO XIAMEN UNIVERSITY   (China)

Author keywords

Invasion; Osteosarcoma; PI3K AKT signaling pathway; Proliferation; Ubiquitin conjugating enzyme E2T (UBE2T)

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN CONJUGATING ENZYME E2T; UNCLASSIFIED DRUG; UBE2T PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; DEFICIENCY; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION; XENOGRAFT;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSFECTION; UBIQUITIN-CONJUGATING ENZYMES;

EID: 84989961527     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504016X14685034103310     Document Type: Article

References (30)

1. Ottaviani, G.; Robert, R. S.; Huh, W. W.; Palla, S.; Jaffe, N. Sociooccupational and physical outcomes more than 20 years after the diagnosis of osteosarcoma in children and adolescents. Cancer 119(20):3727-3736; 2013.
2. Ottaviani, G.; Jaffe, N. The etiology of osteosarcoma. Cancer Treat. Res. 152(152):15-32; 2009.
3. Damron, T. A.; Ward, W. G.; Stewart, A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin. Orthop. Relat. Res. 459(459): 40-47; 2007.
4. Wang, F.; Ke, Z. F.; Wang, R.; Wang, Y. F.; Huang, L. L.; Wang, L. T. Astrocyte elevated gene-1 (AEG-1) promotes osteosarcoma cell invasion through the JNK/c-Jun/MMP-2 pathway. Biochem. Biophys. Res. Commun. 452(4):933- 939; 2014.
5. Schwartz, C. L.; Gorlick, R.; Teot, L.; Krailo, M.; Chen, Z.; Goorin, A.; Grier, H. E.; Bernstein, M. L.; Meyers, P. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J. Clin. Oncol. 25(15):2057-2062; 2007.
6. Ferrari, S.; Palmerini, E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr. Opin. Oncol. 19(4):341-346; 2007.
7. Zhang, P.; Yang, Y.; Zweidlermckay, P. A.; Hughes, D. P. M. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 14(10):2962-2969; 2008.
8. Joenje, H.; Patel, K. J. The emerging genetic and molecular basis of Fanconi anaemia. Nat. Rev. Genet. 2(6):446-457; 2001.
9. Alpi, A.; Langevin, F.; Mosedale, G.; Machida, Y. J.; Dutta, A.; Patel, K. J. UBE2T, the Fanconi anemia core complex, and FANCD2 are recruited independently to chromatin: A basis for the regulation of FANCD2 monoubiquitination. Mol. Cell. Biol. 27(24):8421-8430; 2007.
10. Rickman, K.; Lach, F.; Abhyankar, A.; Donovan, F.; Sanborn, E.; Kennedy, J.; Sougnez, C.; Gabriel, S.; Elemento, O.; Chandrasekharappa, S. Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T subtype of Fanconi anemia. Cell Rep. 12(1):35-41; 2015.
11. Yu, H.; Xiang, P.; Pan, Q.; Huang, Y.; Xie, N.; Zhu, W. Ubiquitin-conjugating enzyme E2T is an independent prognostic factor and promotes gastric cancer progression. Tumor Biol; 2016.
12. Zhou, M. J.; Chen, F. Z.; Chen, H. C. Ubiquitination involved enzymes and cancer. Med. Oncol. 31(8):1-7; 2014.
13. Machida, Y. J.; Machida, Y.; Chen, Y.; Gurtan, A. M.; Kupfer, G. M.; D'Andrea, A. D.; Dutta, A. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol. Cell 23(4):589-596; 2006.
14. Brand, T. M.; Iida, M.; Luthar, N.; Starr, M. M.; Huppert, E. J.; Wheeler, D. L. Nuclear EGFR as a molecular target in cancer. Radiother. Oncol. 108(3):370-377; 2013.
15. Corson, T. W.; Huang, A. M.; Gallie, B. L. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 24(30):4741-4753; 2005.
16. Takat, R.; Katagiri, T.; Kanehir, M.; Tsunod, T.; Shuin, T.; Miki, T.; Namiki, M.; Kohri, K.; Matsushit, Y.; Fujiok, T. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin. Cancer Res. 11(7):2625-2636; 2005.
17. Hao, J.; Xu, A.; Xie, X.; Tian, T.; Gao, S.; Xiao, X.; He, D. Elevated expression of UBE2T in lung cancer tumors and cell lines. Tumour Biol. 29(3):195-203; 2008.
18. Kikuchi, T.; Daigo, Y.; Katagiri, T.; Tsunoda, T.; Okada, K.; Kakiuchi, S.; Zembutsu, H.; Furukawa, Y.; Kawamura, M.; Kobayashi, K. Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22(14):2192-2205; 2003.
19. Wen, M.; Yongwon, K.; Wang, Y.; Mao, J. H.; Wei, G. Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer. Oncotarget 6(28):25226- 25239; 2015.
20. Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-Time quantitative PCR and the 2 -ΔΔC T method. Methods 25(4):402-408; 2001.
21. Hu, W.; Xiao, L.; Cao, C.; Hua, S.; Wu, D. UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3β/β-catenin pathway. Oncotarget 7(12):15161-15172; 2016.
22. Ren, W.; Liu, Y.; Wan, S.; Fei, C.; Wang, W.; Chen, Y.; Zhang, Z.; Wang, T.; Wang, J.; Zhou, L. BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways. PLoS One 9(5):e96816; 2014.
23. Brader, S.; Eccles, S. A. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 90(1):2-8; 2004.
24. Qiao, M.; Chang, X.; Jing, F.; Rojanasakul, Y.; Jiang, B. H. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal. 18(12):2262-2271; 2007.
25. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 25. 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2(7): 489- 501; 2002.
26. Wong, K. K.; Engelman, J. A.; Cantley, L. C. Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev. 20(1): 87-90; 2010.
27. Manning, B. D.; Cantley, L. C. AKT/PKB signaling: Navigating downstream. Cell 129(7):1261-1274; 2007.
28. Cheung, A. K. L.; Ip, J. C. Y.; Chu, A. C. H.; Yue, C.; Leong, M. M. L.; Ko, J. M. Y.; Shuen, W. H.; Hong, L. L.; Lung, M. L. PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma. Oncotarget 6(15):13434-13447; 2015.
29. Zhang, B.; Shi, Z. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: The role of Akt and nuclear factor-kappaB. Anticancer Drugs 21(3):288-296; 2010.
30. Luetke, A.; Meyers, P. A.; Lewis, I.; Juergens, H. Osteosarcoma treatment-Where do we stand A state of the art review. Cancer Treat. Rev. 40(4):523-532; 2014.